Announcement from the nomination committee concerning the Annual General Meeting 2016

The nomination committee consisting of Axel Calissendorff, chairman (appointed by Flerie Participation AB), Lars Backsell (chairman of the board of Recipharm), Johan Lannebo (appointed by Lannebo Fonder) and Ossian Ekdahl (appointed by första AP-Fonden). 

The nomination committee proposes the re-election of board members: Marianne Dicander Alexandersson, Lars Backsell, Anders G. Carlberg, Thomas Eldered, Tony Sandell and Carlos von Bonhorst.

The nomination committee proposes the election of Helena Levander and Wenche Rolfsen as new board members.

Helena Levander, born 1957, holds a B.Sc degree from Stockholm School of Economics in Stockholm and has a broad experience in the field of finances as well as from previous and current board assignments.

Wenche Rolfsen, born 1952, holds a Pharmacist degree, Pharm. Dr, Uppsala, has over 30 years’ experience from leading operative positions in the field of life science as well as from previous and current board assignments.

Re-election of Lars Backsell as chairman of the board is furthermore proposed.

Joan Traynor and Göran Pettersson have declined the re-election.

The nomination committee´s other proposals such as chairs of meetings, fees, how the nomination committee shall submit the recommendation to the AGM 2017 and how the nomination committee shall be appointed will be published on the website and will be announced in the notice of the AGM.

Recipharm’s Annual General Meeting will be held on 28 April 2016 at 1 pm on Recipharm AB’s premises at Lagervägen 7, 136 50 Jordbro.

In the event of any questions please contact:
Axel Calissendorff, chairman of the nomination committee, telephone: +46 768 40 91 03

or

Lars Backsell, member of the nomination committee, telephone: +46 8 602 52 00

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,700 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.4 billion and the Company operates development and manufacturing facilities in France, Germany, Italy, Israel, Portugal, Spain, Sweden and the UK and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com